Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women with Breast Cancer

Cosette D. Champion, Samantha M. Thomas, Jennifer K. Plichta, Edgardo Parrilla Castellar, Laura H. Rosenberger, Rachel A. Greenup, Terry Hyslop, E. Shelley Hwang, Oluwadamilola M. Fayanju

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

PURPOSE:We sought to examine tumor subtype, stage at diagnosis, time to surgery (TTS), and overall survival (OS) among Hispanic patients of different races and among Hispanic and non-Hispanic (NH) women of the same race.METHODS:Women 18 years of age or older who had been diagnosed with stage 0-IV breast cancer and who had undergone lumpectomy or mastectomy were identified in the National Cancer Database (2004-2014). Tumor subtype and stage at diagnosis were compared by race/ethnicity. Multivariable linear regression and Cox proportional hazards modeling were used to estimate associations between race/ethnicity and adjusted TTS and OS, respectively.RESULTS:A total of 44,374 Hispanic (American Indian [AI]: 79 [0.2%]; Black: 1,011 [2.3%]; White: 41,126 [92.7%]; Other: 2,158 [4.9%]) and 858,634 NH women (AI: 2,319 [0.3%]; Black: 97,206 [11.3%]; White: 727,270 [84.7%]; Other: 31,839 [3.7%]) were included. Hispanic Black women had lower rates of triple-negative disease (16.2%) than did NH Black women (23.5%) but higher rates than did Hispanic White women (13.9%; P <.001). Hispanic White women had higher rates of node-positive disease (23.2%) versus NH White women (14.4%) but slightly lower rates than Hispanic (24.6%) and NH Black women (24.5%; P <.001). Hispanic White women had longer TTS versus NH White women regardless of treatment sequence (adjusted means: adjuvant chemotherapy, 42.71 v 38.60 days; neoadjuvant chemotherapy, 208.55 v 201.14 days; both P <.001), but there were no significant racial differences in TTS among Hispanic patients. After adjustment, Hispanic White women (hazard ratio, 0.77 [95% CI, 0.74 to 0.81]) and Black women (hazard ratio, 0.75 [95% CI, 0.58 to 0.96]) had improved OS versus NH White women (reference) and Black women (hazard ratio, 1.15 [95% CI, 1.12 to 1.18]; all P <.05).CONCLUSION:Hispanic women had improved OS versus NH women, but racial differences in tumor subtype and nodal stage among Hispanic women highlight the importance of disaggregating racial/ethnic data in breast cancer research.

Original languageEnglish
Pages (from-to)E827-E838
JournalJCO Oncology Practice
Volume18
Issue number5
DOIs
StatePublished - May 1 2022

Fingerprint

Dive into the research topics of 'Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women with Breast Cancer'. Together they form a unique fingerprint.

Cite this